Status:
COMPLETED
Airway Clearance Study
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to evaluate how the airways in COPD patients, compared to healthy volunteers, absorb steroid drugs from Symbicort Turbuhaler and Seretide Diskus. The blood concentrations o...
Eligibility Criteria
Inclusion
- COPD patients: ≥40 years of age, Diagnosed COPD with symptoms ≥1 year, Pre-bronchodilatory FEV1 ≤55% of PN, Productive cough with expectoration.
- Healthy volunteers: ≥18 years of age, Healthy, Pre-bronchodilatory FEV1 \>80% of PN, Non-smoker
Exclusion
- COPD patients: Current respiratory tract disorder other than COPD, Asthma before 40 years of age, Significant or unstable cardiovascular disorder,
- Healthy volunteers: Use of any regular medication or therapy, Pregnancy or breast-feeding,
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00379028
Start Date
September 1 2006
End Date
July 1 2007
Last Update
January 24 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lund, Sweden
2
Research Site
Nottingham, United Kingdom